SEARCH:   Advanced

Blood, 1 March 2005, Vol. 105, No. 5, pp. 2016-2022. Prepublished online as a Blood First Edition Paper on September 16, 2004; DOI 10.1182/blood-2004-05-1915. This Article Full Text (PDF) All Versions of this Article: 2004-05-1915v1 105/5/2016    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Zeng, Y. Articles by Katsanis, E. Search for Related Content PubMed PubMed Citation Articles by Zeng, Y. Articles by Katsanis, E. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted May 19, 2004 Accepted September 3, 2004 Induction of BCR-ABL specific immunity following vaccination with Chaperone Rich Cell Lysates (CRCL) derived from BCR-ABL+ tumor cells Yi Zeng, Michael W Graner, Sylvia Thompson, Marilyn Marron, and Emmanuel Katsanis* Department of Pediatrics, Steele Memorial Children's Research Center, University of Arizona, Tucson, AZ, USA * Corresponding author; email: katsanis{at}peds.arizona.edu. We have previously reported that chaperone rich cell lysates (CRCL) derived from the BCR-ABL+ 12B1 leukemia activate dendritic cells (DCs) and stimulate leukemia specific immune responses. Since CRCL contain a variety of heat shock/chaperone proteins, we theorized that CRCL obtained from BCR-ABL+ leukemias are likely to chaperone BCR-ABL derived fusion peptides and that DCs pulsed with 12B1 CRCL could cross-present BCR-ABL fusion peptides to T cells. We found that splenocytes from mice vaccinated with BCR-ABL+ leukemia-derived CRCL secreted interferon- (IFN-) when re-stimulated with a BCR-ABL peptide, GFKQSSKAL, indicating that BCR-ABL peptides are chaperoned by leukemia-derived CRCL. We next eluted peptides from 12B1 leukemia-derived CRCL and used HPLC fractions to re-stimulate splenocytes harvested from mice vaccinated with DC/GFKQSSKAL or DC/12B1 CRCL. We found that the same peptide fractions derived from 12B1 CRCL and from "re-fractionated" GFKQSSKAL stimulated IFN- production, suggesting the presence of BCR-ABL peptides in the peptide repertoire of 12B1 CRCL. We also demonstrated that immunization with DCs loaded with leukemia-derived CRCL induced BCR-ABL specific cytotoxic T lymphocytes (CTLs) in vivo. Moreover, mice immunized with DC pulsed with 12B1-derived CRCL had superior survival (60%) when compared to those immunized with DC pulsed with BCR-ABL peptide (20%), indicating that CRCL vaccines provide additional immune stimulus over and above individual peptide vaccination. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: G. Li, S. Andreansky, G. Helguera, M. Sepassi, N. Janikashvili, J. Cantrell, C. L. LaCasse, N. Larmonier, M. L. Penichet, and E. Katsanis A chaperone protein-enriched tumor cell lysate vaccine generates protective humoral immunity in a mouse breast cancer model Mol. Cancer Ther., March 1, 2008; 7(3): 721 - 729. [Abstract] [Full Text] [PDF] K. L. Kislin, M. T. Marron, G. Li, M. W. Graner, and E. Katsanis Chaperone-rich cell lysate embedded with BCR-ABL peptide demonstrates enhanced anti-tumor activity against a murine BCR-ABL positive leukemia FASEB J, July 1, 2007; 21(9): 2173 - 2184. [Abstract] [Full Text] [PDF] M. W. Graner and D. D. Bigner Chaperone proteins and brain tumors: Potential targets and possible therapeutics Neuro-oncol, July 1, 2005; 7(3): 260 - 278. [Abstract] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020